scispace - formally typeset
G

Guy Simonnet

Researcher at University of Bordeaux

Publications -  116
Citations -  5749

Guy Simonnet is an academic researcher from University of Bordeaux. The author has contributed to research in topics: Hyperalgesia & Neuropeptide FF. The author has an hindex of 38, co-authored 116 publications receiving 5566 citations. Previous affiliations of Guy Simonnet include Université Bordeaux Segalen & French Institute of Health and Medical Research.

Papers
More filters
Journal ArticleDOI

Long-lasting Hyperalgesia Induced by Fentanyl in Rats: Preventive Effect of Ketamine

TL;DR: Fentanyl activates NMDA pain facilitatory processes, which oppose analgesia and lead to long-lasting enhancement in pain sensitivity, and the higher the fentanyl dose used, the more pronounced was the fentanyl-induced hyperalgesia.
Journal ArticleDOI

Opioid-induced hyperalgesia: abnormal or normal pain?

TL;DR: In this article, the authors examined experimental evidences which indicate that exogenous opioids simultaneously activate both inhibitory and facilitatory pain systems leading to a longlasting enhancement in pain sensitivity after analgesia.
Journal ArticleDOI

The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance.

TL;DR: The results indicate that sustained NMDA-receptor blocking could be a fruitful therapy for improving postoperative morphine effectiveness and that sustained ketamine pretreatment had no analgesic effect per se at the dose used herein.
Journal ArticleDOI

Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process.

TL;DR: It is shown that both magnitude and duration of heroin-induced delayed hyperalgesia increase with intermittent heroin administrations, leading to an apparent decrease in the analgesic effectiveness of a given heroin dose, suggesting a neuroadaptive process in which NMDA systems play a critical role.
Journal ArticleDOI

RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia

TL;DR: The discovery of a potent and selective NPFF receptor antagonist, RF9, that can be administered systemically and indicate that NPFF receptors are part of a bona fide antiopioid system and that selective antagonists of these receptors could represent useful therapeutic agents for improving the efficacy of opioids in chronic pain treatment.